Toggle Summary Apr 02, 2013
Onconova Appoints Ajay Bansal as Chief Financial Officer
View HTML
Toggle Summary Jan 09, 2013
GVK Biosciences and Onconova Therapeutics Establish Novel Joint Development Partnership to Advance New Drugs for Cancer
View HTML
Toggle Summary Dec 10, 2012
Onconova Presents Positive Clinical Results for Rigosertib at ASH Meeting
Three Trials Demonstrate Safety and Tolerability in Hematological Malignancies
View HTML
Toggle Summary Oct 09, 2012
Onconova Appoints Dr. Thomas J. McKearn as President, Research and Development
View HTML
Toggle Summary Oct 03, 2012
Onconova Presents Positive Clinical Trial Results for Radiation Injury Protector Ex-RAD®
View HTML
Toggle Summary Sep 19, 2012
Baxter and Onconova Announce European Licensing Agreement for Anti-Cancer Compound Rigosertib
Rigosertib in Late-Stage Studies for MDS and Pancreatic Cancer
View HTML
Toggle Summary Jun 01, 2012
Onconova Presents Clinical Trial Data for Oral Rigosertib at ASCO Annual Meeting
Two Clinical Trials Assessed Oral Safety and Bioavailability
View HTML
Toggle Summary May 10, 2012
Onconova Advances Oral Rigosertib to Phase II Clinical Trial in Myelodysplastic Syndromes
Complete Phase I Data to be Reported at ASCO 2012 Annual Meeting
View HTML
Toggle Summary Jul 08, 2011
Onconova and SymBio Complete License Agreement for Rigosertib, a Phase III Stage Multi-Kinase Inhibitor for Cancer
NEWTOWN, Pa. and TOKYO--( BUSINESS WIRE )-- Onconova Therapeutics, Inc., and SymBio Pharmaceuticals Limited announced today that they will collaborate to develop and commercialize rigosertib in Japan and Korea. Onconova is conducting late-stage clinical trials with rigosertib (ON 01910.Na) in the
View HTML
